News

The application is supported by results from the SUMMIT trial. A decision is expected by December 30, 2026.

Peg-interferon-alfa2a (peg-IFN-α) offers a promising approach for treating bone disease in non-advanced systemic mastocytosis.

The presence of genetic trait hereditary alpha-tryptasemia can complicate testing and diagnosis of mast cell disorders, including SM.

Researchers are investigating several potential treatment options that target the underlying disease process in indolent SM.

Aggressive SM should be considered in older adults with unexplained symptoms when no primary cancer is identified.

A new study reveals that sFcεRI acts as a biomarker of systemic mastocytosis severity while potentially protecting against anaphylaxis.

Some therapies in SM may lead to complications such as insomnia.

Needle-free epinephrine could significantly improve response time to severe allergic reactions, a new study suggests.

KIT-targeting drugs can lower abnormal mast cell burden and reduce the frequency and severity of life-threatening reactions.

This study highlights the efficacy of a new method developed for the genetic diagnosis of SM.